How to continue Strattera after moving to Pennsylvania

If you’re struggling with ADHD symptoms and wondering whether you can get help online, you’re not alone. Telehealth has transformed how people access mental healthcare—but navigating the rules around ADHD medication can feel confusing, especially with changing federal regulations and state-specific laws.

The good news? Yes, you can receive ADHD medication through telehealth in most cases. Whether you need a stimulant like Adderall or a non-stimulant like Strattera, licensed providers can evaluate, diagnose, and prescribe ADHD medications during video appointments. However, the specifics depend on the medication type, your state, and current federal rules.

This comprehensive guide breaks down everything you need to know about getting ADHD medication via telehealth in 2025—including what’s legal, what to expect during your appointment, and how to choose a reputable provider.

Understanding ADHD Medications: Stimulants vs. Non-Stimulants

ADHD medications fall into two main categories, and the telehealth rules differ significantly between them:

Stimulant Medications (Schedule II Controlled Substances)

Examples: Adderall (amphetamine), Ritalin (methylphenidate), Vyvanse (lisdexamfetamine), Concerta

Federal Status: These are Schedule II controlled substances regulated by the DEA. Under normal circumstances, the Ryan Haight Act of 2008 requires an in-person medical evaluation before a provider can prescribe controlled substances via telehealth.

Current Exception: Since the COVID-19 pandemic, the DEA has temporarily waived this in-person requirement. The most recent extension runs through December 31, 2025, allowing qualified providers to prescribe stimulant ADHD medications via telehealth without a prior face-to-face visit. A fourth extension for 2026 is under review, but nothing is finalized yet.

Non-Stimulant Medications (Not Controlled)

Examples: Strattera (atomoxetine), Qelbree (viloxazine), Intuniv (guanfacine), Kapvay (clonidine)

Federal Status: Non-stimulant ADHD medications are not classified as controlled substances by the DEA. This means they’ve never been subject to the Ryan Haight Act’s in-person exam requirement.

Telehealth Availability: Providers can prescribe non-stimulant ADHD medications via telehealth just as they would any other non-controlled prescription medication. This has been consistently legal before, during, and after the pandemic—with no special federal restrictions.

The key takeaway? If you’re seeking a non-stimulant like Strattera, telehealth prescribing is straightforward and fully legal nationwide. For stimulant medications, access is currently available but depends on temporary federal flexibilities that may change in 2026.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Rules: What’s Allowed Right Now?

The DEA’s Temporary Telehealth Flexibilities

In March 2020, the DEA issued emergency rules allowing healthcare providers to prescribe Schedule II-V controlled substances via telehealth without an initial in-person examination. This was a dramatic shift from previous policy and opened the door for remote ADHD treatment.

Current Status (December 2025):

• The DEA’s ‘Third Temporary Extension’ keeps these flexibilities in place through December 31, 2025
• Providers with valid DEA registrations can prescribe controlled ADHD medications (stimulants) via audio-visual telehealth
• No in-person visit is required before the initial prescription
• Standard prescribing safeguards still apply (proper evaluation, medical necessity, ongoing monitoring)

What Happens in 2026?

The DEA is working on permanent telehealth prescribing regulations, but no final rules have been published. Options include:

1. Another extension of the current flexibilities (likely, given recent patterns)
2. New permanent rules that may require conditions like special DEA registration for telehealth providers or periodic in-person visits
3. Return to pre-pandemic rules requiring in-person exams (least likely, but legally possible if extensions expire)

The telehealth industry and medical associations are advocating for permanent, reasonable telehealth prescribing pathways. Meanwhile, a proposed ‘Special Registration’ framework would allow qualified providers to prescribe controlled substances via telehealth under enhanced safety protocols—but this remains pending.

Bottom line: For now, stimulant prescribing via telehealth is legal under federal law through the end of 2025. Patients and providers should stay informed about potential changes in early 2026.

Ryan Haight Act: The Background Law

Understanding the Ryan Haight Act helps clarify why ADHD telehealth rules are complicated. This 2008 federal law was passed to prevent illegal online pharmacies from distributing controlled substances without legitimate medical oversight.

The law generally prohibits prescribing controlled substances online unless the practitioner has conducted at least one in-person medical evaluation. However, it includes exceptions for:

• Telemedicine during public health emergencies (the current basis for flexibility)
• Certain Department of Veterans Affairs and Indian Health Service programs
• Consultations by specialists in certain circumstances

Non-controlled medications were never covered by the Ryan Haight Act, which is why Strattera and similar non-stimulants have always been available via telehealth.

State-by-State Variations: Where You Live Matters

While federal law sets the baseline, state laws add another layer of regulation that can be more restrictive. Here’s what you need to know about key states:

States with Special Telehealth Requirements

New York: In May 2025, New York implemented strict rules requiring an in-person evaluation before prescribing any controlled substance via telemedicine. This means for stimulant ADHD medications, NY residents must have an initial face-to-face visit (either with the telehealth provider or another qualified physician). Non-stimulants like Strattera remain available via telehealth without in-person requirements.

Alabama: One of the strictest states for telehealth. Alabama requires an in-person visit within 12 months of ongoing telehealth treatment, or a qualified healthcare professional must be physically present with the patient during the telehealth appointment. However, mental health services are exempt from these rules, which may cover psychiatric ADHD treatment. Non-controlled medications face fewer restrictions.

Florida: Generally prohibits telehealth prescribing of Schedule II stimulants unless prescribed for a psychiatric condition. Fortunately, ADHD qualifies as a psychiatric disorder, so stimulant prescriptions via telehealth are permitted under this exception. Florida also requires prescription monitoring program (PMP) checks before every controlled substance prescription.

Texas: Very telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. However, nurse practitioners and physician assistants face significant restrictions—they can only prescribe Schedule II medications (including stimulants) in hospital or hospice settings, not typical outpatient telehealth.

New Hampshire: Recently liberalized its telehealth rules. As of August 2025, NH removed prior in-person requirements and now only requires an annual follow-up evaluation (which can be conducted via telehealth) for ongoing controlled substance prescriptions.

States with Favorable Telehealth Policies

California, Illinois, Pennsylvania, Georgia, and most other states allow telehealth prescribing of ADHD medications in accordance with federal rules. These states don’t impose additional in-person visit requirements beyond what the DEA mandates (currently waived through 2025).

That said, all states require:

• The provider must be licensed in the patient’s state
• Standard medical evaluation and diagnostic criteria must be met
• Ongoing monitoring and follow-up care
• Compliance with prescription monitoring programs where applicable

Who Can Prescribe ADHD Medications Via Telehealth?

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all 50 states, provided they:

• Hold a valid medical license in the patient’s state
• Have a DEA registration (for controlled substances)
• Follow applicable state telehealth regulations
• Meet standard of care requirements for diagnosis and treatment

Nurse Practitioners (NPs)

NP prescribing authority varies significantly by state:

Full Practice Authority States (including New York, Illinois, New Hampshire): NPs can practice independently and prescribe Schedule II-V controlled substances, including stimulant ADHD medications, after meeting experience and education requirements.

Collaborative Practice States (including California, Florida, Pennsylvania): NPs must work under a physician collaboration agreement. Their ability to prescribe stimulants depends on state-specific rules and the scope of their collaborative agreement.

Restricted States (including Texas, Georgia): NPs face significant limitations on Schedule II prescribing. For example:

• Texas: NPs can only prescribe Schedule II medications in hospital or hospice settings—not in typical outpatient telehealth practice
• Georgia: NPs cannot prescribe Schedule II controlled substances even with physician oversight

For non-stimulant medications: NPs in all states can prescribe Strattera and other non-controlled ADHD medications via telehealth, typically under at least a collaborative agreement.

Physician Assistants (PAs)

Similar to NPs, PA prescribing authority depends on state law and their supervising physician relationship. Most states allow PAs to prescribe controlled substances under appropriate supervision, but some impose supply limits or setting restrictions similar to those for NPs.

Psychiatrists and Psychiatric Nurse Practitioners

Mental health specialists often have the most experience with ADHD diagnosis and medication management. Psychiatric providers (MD/DO psychiatrists and psychiatric mental health nurse practitioners) follow the same general rules as other prescribers but bring specialized expertise in complex cases or co-occurring mental health conditions.

What to Expect During a Telehealth ADHD Evaluation

Legitimate telehealth ADHD services don’t just hand out prescriptions. Here’s what a proper evaluation should include:

Comprehensive Clinical Interview

Your provider will conduct a detailed video consultation covering:

• Current symptoms and how they impact daily life (work, relationships, school)
• Symptom history, including onset in childhood (ADHD is a neurodevelopmental condition)
• Symptoms in multiple settings (not just work or just home)
• Medical history, including cardiovascular issues
• Mental health history, including anxiety, depression, or substance use
• Current medications and supplements
• Family history of ADHD or other conditions

Standardized Assessment Tools

Many providers use validated ADHD rating scales such as:

• Adult ADHD Self-Report Scale (ASRS)
• Conners’ Adult ADHD Rating Scales
• Barkley Adult ADHD Rating Scale

These questionnaires help objectively measure symptom severity and track treatment response.

Collateral Information

For a thorough diagnosis, providers may request:

• Past medical or psychiatric records
• School records or report cards (especially for adults diagnosed later in life)
• Input from family members or close contacts who can verify symptoms
• Previous ADHD testing or evaluations

Medical Screening

Before prescribing ADHD medications, especially stimulants, providers must screen for:

• Cardiovascular risk factors (heart disease, high blood pressure, arrhythmias)
• Mental health conditions that could be worsened (bipolar disorder, psychosis)
• Substance use history or active substance use disorders
• Pregnancy or breastfeeding status
• Other medications that might interact

Treatment Discussion

A quality provider will discuss:

• Medication options (stimulant vs. non-stimulant, different formulations)
• Expected benefits and timeline
• Potential side effects
• Non-medication treatments (therapy, coaching, lifestyle changes)
• Monitoring plan and follow-up schedule
• What to do if side effects occur

Red flags: Be wary of any service that:

• Guarantees a prescription before evaluation
• Requires only a brief questionnaire with no video consultation
• Doesn’t ask about medical history or cardiovascular screening
• Offers medication without discussing risks or alternatives
• Pressures you to choose stimulants over non-stimulants

Understanding Strattera: A Telehealth-Friendly Option

Since Strattera (atomoxetine) is not a controlled substance, it’s worth understanding as a reliable ADHD treatment option that’s fully accessible via telehealth.

How Strattera Works

Unlike stimulants that work on dopamine, Strattera is a selective norepinephrine reuptake inhibitor (SNRI). It helps improve attention and reduce hyperactivity by increasing norepinephrine levels in the brain.

Key characteristics:

• Not a controlled substance: No abuse potential, easier prescribing rules
• Longer onset: Takes 4-6 weeks to reach full effectiveness (unlike stimulants which work same-day)
• 24-hour coverage: Provides consistent symptom control throughout the day
• Lower abuse risk: Appropriate for patients with substance use history
• Flexible prescribing: Can be prescribed with refills and in 90-day supplies

Who Might Prefer Strattera?

Strattera may be preferred for patients who:

• Have a history of substance abuse or addiction concerns
• Experience significant stimulant side effects (insomnia, appetite suppression, anxiety)
• Have co-occurring anxiety disorders
• Need medication coverage that extends into evening hours
• Want to avoid the stigma sometimes associated with controlled substances
• Live in states with stricter stimulant prescribing rules

Strattera Considerations

While Strattera is effective for many patients, it’s important to know:

• Takes longer to work: Requires patience during the initial 4-6 week period
• Different side effect profile: Can cause nausea, decreased appetite, fatigue, or mood changes in some patients
• FDA warnings: Carries a black box warning for increased suicidal thinking in children and adolescents (though risk appears low)
• Liver monitoring: Rare cases of liver damage mean providers should monitor liver function
• Blood pressure effects: Should be monitored, especially in patients with hypertension

Telehealth Access to Strattera

Since Strattera isn’t controlled, telehealth prescribing is straightforward:

• No in-person exam required by federal law
• No DEA restrictions on electronic prescribing
• No refill limitations (unlike Schedule II stimulants requiring new prescriptions monthly)
• Available in all 50 states via telehealth without special exceptions
• No mandatory prescription monitoring checks (though providers review medication history as good practice)

This makes Strattera an excellent option for patients who want the convenience of pure telehealth care without navigating controlled substance regulations.

Prescription Monitoring Programs and Safety Protocols

Even when prescribing is legal, responsible providers implement safety measures to prevent misuse and ensure appropriate care.

What Are Prescription Drug Monitoring Programs (PDMPs)?

PDMPs are state-run electronic databases that track controlled substance prescriptions. They help providers identify:

• Patients receiving prescriptions from multiple providers (‘doctor shopping’)
• Potentially dangerous drug combinations
• Patterns suggesting misuse or diversion
• Early refill requests

State PDMP Requirements

Many states now mandate that prescribers check the PDMP before prescribing controlled substances:

Check Every Time:

• Florida requires PDMP review before each controlled substance prescription
• Alabama requires checks for most controlled prescriptions

Check Initially + Periodic:

• California requires checks at least every 4 months for ongoing controlled substance therapy
• Pennsylvania requires initial check plus every 90 days
• New Hampshire requires checking before each controlled substance prescription
• Georgia requires initial check and at least every 90 days

Recommended But Not Mandated:

• Some states don’t legally require PDMP checks but professional guidelines strongly recommend them
• Many providers voluntarily check even when not required

Note: PDMP mandates typically apply only to controlled substances. For Strattera and other non-controlled ADHD medications, PDMP checks aren’t legally required, but thoughtful providers often review them anyway to understand the complete picture of a patient’s medication history.

Additional Safety Measures

Reputable telehealth ADHD providers may also:

• Use identity verification to confirm patient identity
• Request photo ID and conduct video verification
• Require periodic urine drug screens for stimulant prescriptions
• Implement treatment agreements outlining expectations
• Coordinate care with primary care providers
• Monitor for signs of misuse (early refills, dose escalation without medical reason, lost prescriptions)
• Use pill counts or pharmacy fill records to verify compliance

The Reality of Telehealth ADHD Prescribing: Recent Scrutiny

The telehealth ADHD space experienced significant growing pains in 2022-2023, leading to increased regulatory oversight and industry reforms.

High-Profile Investigations

Major telehealth startups like Cerebral and Done came under DEA and Department of Justice investigation for allegedly:

• Over-prescribing stimulant medications without adequate evaluation
• Using aggressive marketing that prioritized revenue over patient care
• Inadequate provider oversight and quality control
• Insufficient documentation of medical necessity

In response, Cerebral announced it would stop prescribing most controlled substances, and the industry faced intense scrutiny from regulators and media.

Industry Response and Best Practices

These controversies led to positive changes across the telehealth ADHD field:

Enhanced Evaluations:

• Longer initial consultations (45-60 minutes becoming standard)
• Use of validated diagnostic tools and rating scales
• More thorough documentation of symptoms and functional impairment
• Careful screening for contraindications and risk factors

Improved Ongoing Care:

• Regular follow-up appointments (monthly initially, then as clinically appropriate)
• Dose optimization based on symptom response and side effects
• Reassessment of diagnosis if treatment isn’t effective
• Coordination with in-person providers when needed

Stricter Provider Oversight:

• Peer review of prescribing patterns
• Clinical guidelines and prescribing protocols
• Training on appropriate telehealth ADHD diagnosis
• Monitoring for red flags or inappropriate prescribing

Patient Education:

• Clear information about medication risks and benefits
• Discussion of non-medication options
• Resources for therapy, coaching, and lifestyle management
• Transparent policies about when in-person care is needed

These improvements ultimately benefit patients by ensuring safer, more effective care while preserving the convenience and accessibility of telehealth.

How to Choose a Reputable Telehealth ADHD Provider

Not all telehealth services are created equal. Here’s what to look for:

Signs of a Quality Service

Thorough Evaluation Process:

• Comprehensive intake questionnaire
• Video consultation with licensed provider
• Use of standardized ADHD rating scales
• Discussion of medical history and screening for contraindications

Licensed, Qualified Providers:

• Doctors, nurse practitioners, or physician assistants licensed in your state
• Specialized training or experience in ADHD
• Valid DEA registration (for controlled substances)

Transparent Practices:

• Clear information about costs and insurance coverage
• Privacy policy compliant with HIPAA
• No guarantees of specific medications
• Information about what happens if medication isn’t appropriate

Comprehensive Care Approach:

• Discussion of both medication and non-medication options
• Recommendation or referral for therapy/coaching
• Follow-up schedule with ongoing monitoring
• Coordination with your other healthcare providers when appropriate

Responsible Prescribing:

• Appropriate screening and safety checks
• Treatment plans tailored to individual needs
• Clear communication about side effects and what to watch for
• Policies for refills, dose changes, and emergency contact

Red Flags to Avoid

Be cautious of services that:

• Promise or guarantee prescriptions before evaluation
• Offer medications based only on a questionnaire (no video visit)
• Use high-pressure sales tactics or aggressive marketing
• Don’t adequately screen medical history
• Offer same-day prescriptions without thorough evaluation
• Have limited or no follow-up care
• Ship medications internationally or from unlicensed pharmacies
• Don’t require or verify your identity
• Seem too easy or too good to be true

Questions to Ask

Before starting with a telehealth ADHD service, consider asking:

1. Are your providers licensed in my state?
2. What does the evaluation process involve?
3. How long is the initial appointment?
4. What if I need a medication you can’t prescribe via telehealth?
5. What’s your follow-up schedule?
6. Do you accept my insurance, or what are the out-of-pocket costs?
7. How do you handle emergencies or urgent questions?
8. Can you coordinate with my primary care doctor or therapist?
9. What happens if treatment isn’t working?
10. How do you stay compliant with changing telehealth regulations?

Klarity Health: Accessible ADHD Care That Puts Patients First

At Klarity Health, we understand that finding quality ADHD care shouldn’t be complicated. Our platform connects you with board-certified providers who specialize in ADHD diagnosis and treatment—all from the comfort of home.

What sets Klarity apart:

Provider Availability: We maintain a robust network of licensed physicians and nurse practitioners across all 50 states, ensuring you can find an appointment that fits your schedule—often within days, not months.

Transparent Pricing: Whether you’re using insurance or paying out-of-pocket, we provide upfront, clear pricing with no hidden fees. Cash-pay options make care accessible even without insurance coverage.

Insurance + Cash Pay Options: We work with most major insurance plans and also offer affordable self-pay rates, giving you flexibility in how you access care.

Comprehensive Approach: Our providers conduct thorough ADHD evaluations using evidence-based diagnostic criteria. We discuss all treatment options—medication and non-medication—and create personalized treatment plans based on your unique needs and circumstances.

Ongoing Support: ADHD management is a journey, not a one-time appointment. We provide regular follow-ups, dose optimization, and ongoing support to ensure your treatment remains effective.

Compliance-First: We stay current with all federal and state regulations, implementing best practices for safe prescribing. Our providers use appropriate screening, monitoring, and documentation to ensure you receive care that’s both effective and compliant.

Whether you’re newly seeking diagnosis or looking for more convenient ongoing care, Klarity provides the expertise and accessibility you need—without the traditional barriers that make ADHD treatment difficult to access.

Insurance Coverage and Costs

Telehealth Insurance Coverage

The good news: Most insurance plans now cover telehealth mental health services at the same rate as in-person visits, thanks to pandemic-era parity laws that many states have made permanent.

What’s typically covered:

• Initial diagnostic evaluation
• Medication management appointments
• Follow-up visits
• Crisis consultations

What may not be covered:

• Some plans limit the number of telehealth visits per year
• Prior authorization may be required for certain medications
• Therapy or coaching (if separate from medication management)

Check with your insurance about:

• Telehealth coverage limits
• In-network vs. out-of-network providers
• Co-pays and deductibles
• Medication coverage (pharmacy benefit)

Out-of-Pocket Costs

For those paying cash or with high-deductible plans:

Initial Evaluation: Typically $150-$300Follow-up Visits: Usually $75-$150Monthly Medication Costs:

• Stimulants (generic): $30-$100
• Stimulants (brand): $200-$400
• Strattera (generic atomoxetine): $40-$150
• Other non-stimulants: $100-$300

Many telehealth platforms, including Klarity, offer competitive cash-pay rates that may be comparable to or lower than traditional in-office visit co-pays.

Medication Assistance Programs

If medication costs are a barrier:

• Check manufacturer websites for patient assistance programs
• Ask about generic alternatives (available for many ADHD medications)
• Compare prices across different pharmacies (GoodRx and similar services can help)
• Discuss cost concerns with your provider—they may adjust the treatment plan to more affordable options

Lifestyle and Non-Medication Strategies

While medication can be highly effective for ADHD, comprehensive treatment often includes non-medication strategies:

Evidence-Based Non-Medication Approaches

Cognitive Behavioral Therapy (CBT): Specifically tailored CBT for ADHD helps develop coping strategies, organizational skills, and addresses negative thought patterns.

ADHD Coaching: Works on practical skill-building in areas like time management, goal-setting, and accountability.

Exercise: Regular physical activity has been shown to improve ADHD symptoms, mood, and executive function.

Sleep Hygiene: Quality sleep is crucial for ADHD management; establishing consistent sleep routines helps.

Nutrition: While no special ‘ADHD diet’ is proven, balanced nutrition and avoiding excessive sugar/processed foods may help some individuals.

Mindfulness and Meditation: Practices that improve attention and reduce impulsivity.

Environmental Modifications: Creating organized spaces, using timers and reminders, minimizing distractions.

Combining Medication and Lifestyle Approaches

The most effective ADHD treatment typically combines medication with behavioral strategies. Your telehealth provider should discuss non-medication options and can refer you to therapists, coaches, or other specialists as needed.

Many people find that medication helps them have the focus and executive function needed to implement lifestyle strategies that might have been impossible before treatment.

Common Questions and Concerns

‘Will I have to take medication forever?’

Not necessarily. Some people benefit from medication only during particularly demanding periods (school, new job, etc.), while others find ongoing medication helpful long-term. ADHD is a chronic condition, but treatment is individualized. Regular reassessment with your provider helps determine what’s working and whether adjustments are needed.

‘What if the first medication doesn’t work?’

It’s common to need medication adjustments. About 70-80% of people with ADHD respond well to stimulants, but finding the right medication and dose often requires trial and error. If a stimulant doesn’t work or causes unacceptable side effects, your provider can try:

• Different stimulant type or formulation
• Dose adjustment
• Different timing of doses
• Non-stimulant alternatives
• Combination approaches

‘Can I use telehealth if I’m already diagnosed?’

Absolutely. Many people use telehealth for ongoing medication management even if they were diagnosed in person. You’ll typically need to provide documentation of your previous diagnosis and treatment history.

‘What about therapy or counseling?’

Many telehealth platforms offer both medication management and therapy services. Some patients see the same provider for both; others work with a prescriber for medication and a separate therapist for counseling. Either approach can work well.

‘Will my employer/school know I’m taking ADHD medication?’

Medical information is confidential and protected by HIPAA. Your provider cannot disclose your diagnosis or treatment without your written consent. However, if you’re requesting accommodations at work or school, you may need to provide documentation—discuss this with your provider.

Looking Ahead: The Future of ADHD Telehealth

What’s Next for Regulations?

While the landscape remains somewhat uncertain, several trends are clear:

Likely Scenario: Continued federal telehealth flexibilities, possibly with new framework requiring periodic in-person visits or special provider registration.

State Evolution: More states are likely to permanently adopt telehealth-friendly policies while implementing appropriate safeguards.

Increased Integration: Better coordination between telehealth and in-person care, with hybrid models becoming standard.

Enhanced Technology: Improved platforms, better integration with electronic health records, and more sophisticated remote monitoring tools.

Advocacy and Policy

Healthcare organizations, patient advocacy groups, and telehealth providers continue pushing for permanent, reasonable telehealth prescribing rules that balance access with safety. Congressional proposals like the TREATS Act aim to further expand telehealth access.

Patients who benefit from telehealth can support these efforts by:

• Sharing their positive experiences with legislators
• Participating in public comment periods when regulations are proposed
• Supporting patient advocacy organizations
• Using services responsibly to demonstrate telehealth’s value

Taking the Next Step

If you’re struggling with ADHD symptoms, telehealth offers a convenient, effective pathway to diagnosis and treatment. Here’s how to get started:

1. Research your options: Look for reputable telehealth services with licensed providers in your state.

2. Check your insurance coverage: Understand what’s covered and what costs you’ll be responsible for.

3. Gather relevant information: Collect any previous medical records, school records, or documentation of your symptoms.

4. Be prepared for a thorough evaluation: Set aside time for a comprehensive initial consultation—this isn’t a quick questionnaire.

5. Be honest and complete: Share your full medical history, symptoms, and any concerns openly with your provider.

6. Commit to follow-up: ADHD treatment requires ongoing monitoring and adjustment. Plan to attend follow-up appointments as recommended.

7. Stay informed: Keep up with any regulatory changes that might affect your care, and maintain open communication with your provider about any concerns.

Take Control of Your ADHD Today

Living with untreated ADHD doesn’t have to be your reality. Whether you’re seeking a initial diagnosis or looking for more convenient ongoing care, telehealth makes effective ADHD treatment more accessible than ever.

Ready to get started? Klarity Health offers comprehensive ADHD evaluations and treatment with board-certified providers who specialize in ADHD care. With appointments available in days, transparent pricing, and both insurance and cash-pay options, getting help has never been easier.

Visit Klarity Health today to schedule your consultation and take the first step toward better focus, productivity, and quality of life.

References

1. Fierce Healthcare. ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth, punts final rule.’ November 2024. Available at: www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ December 2025. Available at: www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog (via National Law Review). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ August 15, 2025. Available at: www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. RxAgent. ‘The Telehealth Compliance Trap: What Providers Need to Know About Prescribing Controlled Substances.’ October 2025. Available at: www.rxagent.co/blog/telehealth-compliance-trap

5. Medical News Today. ‘Is Strattera a controlled substance?’ January 14, 2025. Available at: www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

This article is for informational purposes only and does not constitute medical advice. ADHD diagnosis and treatment should be individualized based on a comprehensive evaluation by a qualified healthcare provider. Regulations discussed are current as of December 2025 and subject to change. Always verify current laws in your state and consult with licensed providers for medical decisions.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment